Myocardial perfusion stress test in women

Isidora Grozdic Milojevic, Katja Petrovic, Olga Radivojevic, Lenka Grujicic, Milica Kotur, Dragana Sobic Saranovic

Article ID: 3030
Vol 5, Issue 2, 2024
DOI: https://doi.org/10.54517/ccr.v5i2.3030
Received: 15 November 2024; Accepted: 18 December 2024; Available online: 29 December 2024; Issue release: 31 December 2024


Download PDF

Abstract

Aim: The utility of the 99mTc-sestamibi myocardial perfusion stress imaging (MPI) over stress echo test (SEHO) in women with intermediate pre-test probability scores. Methodology: Our study included 98 women with suspected ischemic heart disease and intermediate pre-test probability scores who underwent MPI and SEHO. They were followed for 26 ± 6 months. The data about MACE and possible coronary angiography were collected. Results: The SEHO test was pathological in 31% of the study population. Almost half of those patients had atypical chest pain. MPI was positive in 32% of the examined group. In the follow-up period, MACE was present in 36 patients: PCI (20), CABG (8), acute coronary syndrome (8). The results of the MPI had a high statistically significant correlation with the coronary angiography findings in the follow-up period (p < 0.001, μ = 0.878). Additionally, the SEHO test and coronary angiography results correlated well (p < 0.05, μ = 0.582). However, MPI test result and SEHO result were not significantly associated with MACE based on Cox proportional hazard analyses (p > 0.05). Conclusion: MPI may be the complementary procedure for the evaluation of heart conditions in women with intermediatepre-test probability scores, since it correlates well with coronary angiography findings.


Keywords

MPI; SEHO coronary angiography; MACE


References

Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Isidora Grozdic Milojevic, Katja Petrovic, Olga Radivojevic, Lenka Grujicic, Milica Kotur, Dragana Sobic Saranovic

License URL: https://creativecommons.org/licenses/by/4.0/


This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).